As the combination of SM6Met and 4-OH-Tam was the only treatment to substantially inhibit all three processes implicated in ER+ breast cancer metastasis, it shows great potential to not only be developed as treatment for primary or early-stage ER+ breast cancer, but also metastatic ER+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.